OTCMKTS:SOLTF Nxera Pharma (SOLTF) Stock Price, News & Analysis $8.22 -1.32 (-13.84%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$8.22▼$8.2250-Day Range$9.43▼$10.5352-Week Range$8.22▼$13.43Volume100 shsAverage Volume1,579 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest Get Nxera Pharma alerts: Email Address Ad Paradigm PressKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… Click here now and learn how to prepare. About Nxera Pharma Stock (OTCMKTS:SOLTF)Nxera Pharma Co., Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications. The company's development products pipeline consists of HTL0039732 for immuno-oncology indications; HTL0048149 for schizophrenia disorders; Daridorexant for the treatment of insomnia; HTL0016878 for schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; PF-06954522 for metabolic diseases; NBI-1117569 for neurology diseases; and NBI-1117570 for central nervous system (CNS) disorders. It is also involved in the development of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; and other discovery and preclinical stage drugs. Nxera Pharma Co., Ltd. has a strategic collaboration with AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily. Nxera Pharma Co., Ltd. was incorporated in 1990 and is headquartered in Tokyo, Japan.Read More SOLTF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SOLTF Stock News HeadlinesSeptember 2, 2024 | markets.businessinsider.comNxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568August 15, 2024 | seekingalpha.comElite Pharmaceuticals, Inc. (ELTP) Q1 2025 Earnings Call TranscriptSeptember 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…August 9, 2024 | globenewswire.comNxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2024July 9, 2024 | globenewswire.comNxera Pharma Webinar Presentation for Q2 FY2024 Financial ResultsJune 26, 2024 | globenewswire.comNxera Pharma Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D MilestoneJune 18, 2024 | globenewswire.comNxera Pharma Publishes its Annual and ESG Reports for the Year ended 31 December 2023May 30, 2024 | globenewswire.comNxera Pharma and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic AreaSeptember 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…May 9, 2024 | finance.yahoo.comNxera Pharma’s partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy AdultsMay 9, 2024 | globenewswire.comNxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2024April 29, 2024 | msn.comFDA Approves X4 Pharmaceuticals' Mavorixafor As First Therapy For Rare Immunodeficiency DisorderApril 17, 2024 | finance.yahoo.comNxera Pharma: Notice of Issuance of New Shares Under the Restricted Stock Unit (RSU) Plan and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Previous Years’ RSU PlanApril 15, 2024 | msn.comNxera and Handok partner for PIVLAZ supply in South KoreaApril 15, 2024 | nasdaq.comNxera Pharma Announces Supply And Distribution Deal With Handok For PIVLAZ In South KoreaApril 15, 2024 | finance.yahoo.comNxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for PIVLAZ™ in South KoreaApril 8, 2024 | finance.yahoo.comNxera Pharma joins the World Orphan Drug AllianceApril 3, 2024 | finance.yahoo.comNxera Pharma Appoints Experienced Senior Strategy Consultant Patrick Branch as Head of Business Development for Japan and APACSee More Headlines Receive SOLTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nxera Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:SOLTF CUSIPN/A CIKN/A Webwww.sosei.com Phone(135) 210-3290FaxN/AEmployees350Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Shinichi Tamura (Age 75)Founder & Chairman of the Board Comp: $1.5MMr. Christopher Cargill (Age 40)Representative Executive Officer, President, CEO & Director Comp: $1.28MMr. Hironoshin Nomura (Age 41)Executive Officer, Executive VP & CFO Mr. Toshihiro MaedaChief Operating OfficerMr. Kieran Johnson F.C.A. (Age 55)Executive Officer, Executive VP & Chief Accounting Officer Dr. Miles CongreveChief Scientific OfficerMr. Kazuhiko Yoshizumi (Age 70)Executive Officer, Executive VP & Chief Compliance Officer Shinichiro NishishitaVP of Investor Relations & Head of Regulatory DisclosuresStacey SouthallAssociate Director & Head of BiophysicsMs. Candelle Chong (Age 35)Executive Officer, Executive VP & Chief of Staff More ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors SOLTF Stock Analysis - Frequently Asked Questions How have SOLTF shares performed this year? Nxera Pharma's stock was trading at $10.00 at the beginning of 2024. Since then, SOLTF shares have decreased by 17.8% and is now trading at $8.22. View the best growth stocks for 2024 here. How do I buy shares of Nxera Pharma? Shares of SOLTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:SOLTF) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nxera Pharma Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nxera Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.